enGene Updates Corporate Presentation with New LEGEND Data, Reiterates Cash Runway
ENGN sits 30% above its 52-week low of $1.4.
Summary
enGene Therapeutics updated its corporate presentation with new interim Phase 2 LEGEND data showing a 54% complete response rate for detalimogene, a favorable safety profile, and progress on a surfactant-enhanced cohort. The company reiterated $285 million in cash, expected to fund operations through potential BLA filing and approval.
Key Events · Product Development and Regulatory · ENGN
-
New LEGEND Interim Data
Pivotal Cohort 1 showed a 54% complete response rate at any time—the primary endpoint—with 91% of CRs occurring at the first assessment and 96.8% of patients free from progression to ≥T2 disease. The safety profile was favorable, reflected in low treatment interruption (2.4%) and discontinuation (2.4%) rates.
-
Surfactant Cohort Progress
The first patients have been enrolled in a LEGEND cohort evaluating detalimogene combined with a polidocanol surfactant bladder rinse. Preclinical data suggest this approach could increase IL-12 expression more than tenfold, potentially improving both efficacy and durability.
-
Cash Runway Reiterated
Management highlighted $285 million in cash, cash equivalents, and marketable securities, which is expected to provide operating flexibility through a potential BLA filing and approval.
-
Near-Term Catalysts
A 12-month data update from the pivotal cohort and initiation of the BLA are expected in the second half of 2026, with potential approval and platform designation in 2027.
Analysis · ENGN · Life Sciences
enGene Therapeutics filed an updated corporate presentation that includes new interim Phase 2 LEGEND trial results for detalimogene in high-risk NMIBC. The data show a 54% complete response rate at any time, with a favorable safety profile and low progression to advanced disease. The presentation also highlights progress on a surfactant bladder rinse cohort designed to boost efficacy, and reiterates $285 million in cash expected to fund operations through a potential BLA filing and approval. This update comes just one month after a drastic 50% workforce reduction and executive departures, making the clinical progress and cash runway reassurance critical for investor confidence.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENGN was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.9M. The 52-week trading range was $1.40 to $12.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.